Ullrich syndrome is a severe congenital musculoskeletal disorder affecting multiple organ systems. The major clinical features include muscle weakness, proximal joint contractures, distal hyper extensibility, kyphoscoliosis, spine rigidity and skin abnormalities. In the severe presentation of the disease, independent walking is not achieved owing to progression of muscle weakness and contractures, and most patients die of respiratory failure during the first to third decades of life. The disease has recently been shown to result from recessive or dominant negative mutations of type VI collagen genes. Collagen VI forms a filamentous network widely distributed in most soft connective tissues and cartilage. It plays important roles in cell-matrix and matrix-matrix interactions, and changes in the expression and localization of collagen VI microfibrils are associated with common musculoskeletal diseases such as osteoarthritis. This application seeks to understand the pathogenesis of Ullrich syndrome and to develop therapies for this disabling and often fatal disease. Mouse models harboring targeted collagen VI mutations will be generated and the structural organization of the extracellular matrix in tendon, joint, muscle and skin will be analyzed to delineate the pathogenic mechanisms of disease progression. The biochemical basis of collagen VI microfibrillar assembly and the effects of disrupting microfibrillar formation during musculoskeletal development will be elucidated. In addition, therapeutic approaches for Ullrich syndrome resulting from recessive and dominant negative mutations will be explored. The proposed studies will lay the groundwork for future therapeutic intervention of genetic and acquired diseases associated with disorganization of collagen VI microfibrils.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR053251-03
Application #
7274779
Study Section
Special Emphasis Panel (ZRG1-MOSS-K (04))
Program Officer
Wang, Yan Z
Project Start
2005-09-21
Project End
2010-08-31
Budget Start
2007-09-01
Budget End
2008-08-31
Support Year
3
Fiscal Year
2007
Total Cost
$323,330
Indirect Cost
Name
Thomas Jefferson University
Department
Dermatology
Type
Schools of Medicine
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Pan, Te-Cheng; Zhang, Rui-Zhu; Arita, Machiko et al. (2014) A mouse model for dominant collagen VI disorders: heterozygous deletion of Col6a3 Exon 16. J Biol Chem 289:10293-307
Pan, Te-Cheng; Zhang, Rui-Zhu; Markova, Dessislava et al. (2013) COL6A3 protein deficiency in mice leads to muscle and tendon defects similar to human collagen VI congenital muscular dystrophy. J Biol Chem 288:14320-31
Arafat, Hwyda; Lazar, Melissa; Salem, Khalifa et al. (2011) Tumor-specific expression and alternative splicing of the COL6A3 gene in pancreatic cancer. Surgery 150:306-15
Izu, Yayoi; Ansorge, Heather L; Zhang, Guiyun et al. (2011) Dysfunctional tendon collagen fibrillogenesis in collagen VI null mice. Matrix Biol 30:53-61
Zhang, Rui-Zhu; Zou, Yaqun; Pan, Te-Cheng et al. (2010) Recessive COL6A2 C-globular missense mutations in Ullrich congenital muscular dystrophy: role of the C2a splice variant. J Biol Chem 285:10005-15
Zou, Yaqun; Zhang, Rui-Zhu; Sabatelli, Patrizia et al. (2008) Muscle interstitial fibroblasts are the main source of collagen VI synthesis in skeletal muscle: implications for congenital muscular dystrophy types Ullrich and Bethlem. J Neuropathol Exp Neurol 67:144-54
Lampe, A K; Zou, Y; Sudano, D et al. (2008) Exon skipping mutations in collagen VI are common and are predictive for severity and inheritance. Hum Mutat 29:809-22